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Background: Despite the magnitude and impact of heart failure (HF) in the United States, 
relatively little data are available that describe the prognosis associated with acute HF,  especially 
from the perspective of a population-based investigation. The purpose of this  nonconcurrent 
 prospective study was to describe the overall, and changing trends therein, prognosis of 
4228 patients discharged from all eleven greater Worcester (MA) medical centers after a 
documented episode of acute HF and factors associated with an increased risk of dying after 
hospital discharge.
Methods: The study population consisted of residents of the Worcester metropolitan area 
 discharged after being hospitalized for acute HF at all greater Worcester medical centers during 
1995 (n = 1783) and 2000 (n = 2445).
Results: The 3-month (20% versus 18%), 1-year (41% versus 38%), and 5-year (84% versus 
82%) death rates were lower in patients discharged from all metropolitan Worcester hospitals in 
2000 versus 1995, respectively. Improving long-term survival rates for patients discharged in 2000 
as compared with 1995 were magnified after controlling for several confounding demographic 
and clinical factors of prognostic importance. A number of potentially modifiable demographic, 
medical history, and clinical factors were associated with an increased risk of dying during the 
first year after hospital discharge for acute HF.
Conclusion: The results of this community-wide observational study suggest improving trends 
in the long-term prognosis after acute HF. Despite these encouraging trends, the long-term 
prognosis for patients with acute HF remains poor, and several at-risk groups can be identified 
for early intervention and increased monitoring efforts.
Keywords: population-based study, long-term prognosis, post-discharge survivors
Introduction
Heart failure (HF) is a major and growing public health and clinical problem in the 
United States and other industrialized nations.1,2 Despite advances in the medical and 
nonpharmacologic management of patients with acute and chronic manifestations 
of HF, the prognosis of patients with HF remains poor.3–8 Given the aging of the 
American population, the improved treatment of coronary heart disease and HF, as 
well as the ongoing epidemics of obesity and diabetes, there is a myriad of reasons to 
believe that the characteristics and prognosis of persons with HF may have changed 
over time. Despite the magnitude and impact of this clinical syndrome, however, few 
contemporary data exist, particularly from the more generalizable perspective of a 
population-based study, describing the long-term prognosis of patients hospitalized 
with decompensated HF, changes over time therein, or the independent predictors of 
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death among representative populations with acute HF. In a 
prior study carried out in the metropolitan Worcester popula-
tion, the long-term prognosis of patients discharged from all 
greater Worcester medical centers after being hospitalized 
for acute HF in 2000 and factors associated with an increased 
risk of dying were examined.8
The objectives of the present community-wide obser-
vational study were to describe the overall prognosis of 
patients discharged from the hospital after acute HF, changing 
trends in the post-discharge survival of these patients, and to 
identify demographic and clinical factors associated with a 
poor long-term prognosis. Residents of the Worcester (MA) 
metropolitan area discharged from all greater Worcester 
medical centers after an episode of documented acute HF in 
1995 and 2000 as part of the Worcester Heart Failure Study 
comprised the population of this report.9,10
Methods
Adult male and female residents of all ages from the Worces-
ter (MA) metropolitan area (2000 census estimate = 478,000) 
hospitalized for possible acute HF at all eleven greater 
Worcester medical centers during 1995 and 2000 comprised 
the study population. For purposes of identifying the study 
population, the medical records of patients with primary or 
secondary International Classification of Diseases, Ninth 
Revision (ICD-9) codes consistent with the possible presence 
of HF were reviewed in a standardized manner.9,10 Patients 
with a discharge diagnosis of HF (ICD-9 code 428) comprised 
the primary diagnostic rubric reviewed for the identification 
of cases of possible HF. In addition, the medical records of 
patients with discharge diagnoses of rheumatic HF (ICD-9 
code 398.9), hypertensive heart and renal disease (ICD-9 
codes 402 and 404, respectively), acute cor pulmonale 
(ICD-9 code 415), other diseases of the endocardium (ICD-9 
code 424), cardiomyopathy (ICD-9 code 425.4), pulmonary 
heart disease and congestion (ICD-9 codes 416.9 and 514, 
respectively), acute lung edema (ICD-9 code 518.4), edema 
(ICD-9 code 782.3), and dyspnea and respiratory abnor-
malities (ICD-9 code 786) were reviewed by trained study 
physicians and nurses to identify patients who may have had 
newly diagnosed acute HF.
The diagnosis of acute HF in greater Worcester residents 
presenting to area hospitals with signs and symptoms of HF 
was defined as the presence of decompensated HF based 
on use of the Framingham Study criteria.11 These criteria 
included the presence of two major criteria (eg, rales and 
distended neck veins) or one major and two minor (eg, night 
cough and dyspnea on ordinary exertion) criteria.
An incident (first) event of acute HF was defined as the 
absence of a prior hospitalization for HF, physician diagnosis 
of HF, or past treatment for HF based on the review of data 
contained in hospital medical records. Patients who devel-
oped HF secondary to admission for another acute illness 
(eg, acute myocardial infarction) or after a procedure or 
surgery (eg, percutaneous coronary intervention) were not 
included. Patients who died during the index hospitaliza-
tion were excluded from the final analytic sample, since the 
aim was to describe the long-term prognosis of discharged 
hospital patients.
Data collection
Information was collected about patient’s demographic, med-
ical history, and clinical characteristics, as well as laboratory 
test results, through the review of information contained in 
hospital medical records. This included information about a 
patient’s age, sex, race/ethnicity, body mass index (BMI), ini-
tial symptoms of HF, physical examination findings, clinical 
characteristics, prior comorbidities (eg, stroke, hypertension, 
diabetes mellitus), and laboratory findings (eg, serum levels 
of glucose, hematocrit, estimated glomerular filtration rate 
[eGFR]).12 Since ejection fraction findings during the index 
hospitalization were available for only one-third of hospital 
survivors of decompensated HF in the present study, this 
variable was not used in the analysis of factors associated 
with long-term prognosis after acute HF.
Physicians’ progress notes and daily medication logs 
were reviewed for the prescribing of selected medications. 
The use of cardiac medications that have been shown to 
be of benefit in improving the prognosis of patients with 
HF (β-blockers, angiotensin receptor blockers, and angio-
tensin-converting enzyme inhibitors), as well as the use of 
medications shown to be effective in relieving the symp-
toms of patients with acute HF (digoxin and diuretics) were 
examined.13 Information about patients’ long-term survival 
status was obtained through the review of hospital medical 
records at all participating medical centers for subsequent 
hospitalizations or medical care contacts, as well as through 
the review of the Social Security Death Index and statewide 
death certificates.
Data analysis
A life-table approach was used to examine long-term mortal-
ity patterns after greater Worcester residents were discharged 
from all metropolitan Worcester medical  centers after a first 
episode of acute HF or a new exacerbation of previously diag-
nosed HF in 1995 and 2000 through the end of 2008,  including 
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patients with varying lengths of long-term follow-up. 
 Long-term all-cause post-hospital-discharge death rates were 
calculated in a standard manner with accompanying 95% 
confidence intervals (CIs). Differences in the distribution of 
selected demographic and clinical characteristics between 
post-discharge decedents and survivors were examined 
using chi-square tests and t-tests for discrete and continu-
ous  variables, respectively. Differences in the long-term 
prognosis of patients discharged from all greater Worcester 
hospitals after acute HF at selected post-discharge time points 
were examined through the use of chi-square tests and the 
log-rank test for statistical significance.
A logistic regression approach was used to identify 
demographic, medical history, laboratory, and clinical 
factors associated with a poor prognosis after HF at 3 and 
12 months after hospital discharge, given the high risk of 
dying at these time points. Multivariable adjusted odds 
ratios (ORs) and accompanying 95% CIs of factors associ-
ated with a poor prognosis at 3 months and at 1 year after 
hospital discharge were calculated in a standard manner. 
These periods were chosen for analysis due to the high death 
rates experienced by patients with acute HF during the first 
several months to 1 year after hospital discharge for HF. 
Since further information was not available about changes in 
patients’ clinical or treatment statuses after being discharged 
from greater Worcester medical centers during the years 
under study, the identification of factors associated with a 
poor prognosis was focused on those that could be identified 
at the time of hospital discharge for HF and that may be ame-
nable to change. The use of various hospital therapies were 
not controlled for in these multivariable adjusted regression 
analyses, due to the nonrandomized observational nature of 
the present noncurrent prospective study and potential for 
confounding by treatment  indication. Further, treatment 
variables were not included in the  multivariable adjusted 
regression models due to the difficulty in interpretation of 
any resultant findings.
Results
Baseline characteristics
After an extensive review of hospital medical records and 
various disease diagnostic rubrics in which cases of possible 
HF might be found, a total of 1949 greater Worcester residents 
were hospitalized for acute HF in the year 1995 and 2587 in 
the year 2000; of these, there were a total of 508 incident 
(initial episode) events of acute HF in 1995 and 645 cases of 
newly diagnosed acute HF in 2000. In 1995, 8.5% of all cases 
of acute HF died during their index hospitalization compared 
with 5.5% of all patients with acute HF in 2000; among 
incident cases of acute HF, 7.9% died in 1995, whereas 5.7% 
died in 2000. After excluding patients who died during their 
index hospitalization, in order to systematically characterize 
the post-discharge prognosis of patients with acute HF, the 
final analytic sample consisted of 1783 hospital survivors in 
1995 and 2445 patients in 2000; of these, 468 were incident 
cases of acute HF in 1995 and 608 in 2000.
The average age of the study population was 76 years, 
57% were women, and approximately three-quarters had 
been previously diagnosed with HF based on a review of 
the information contained in hospital medical records. 
There were no appreciable differences in the average age 
(75 years versus 76 years), proportion of women (58% 
versus 57%), or percentage of patients presenting with a 
first episode of HF (26% versus 25%) between hospital 
survivors of HF in 1995 as compared with those discharged 
in 2000, respectively.
Long-term death rates and changing 
trends therein
In examining the long-term prognosis for all patients 
 discharged after a confirmed episode of acute HF, the 
3-month, 1-year, and 5-year death rates were 18.8% 
(95% CI 17.6%–20.0%), 39.7% (95% CI 38.2%–41.2%), 
and 82.9% (95% CI 81.7%–84.0%), respectively.
Patients discharged from all greater Worcester medical 
centers in 2000 after hospitalization for decompensated HF 
experienced slightly lower all-cause death rates than patients 
discharged in 1995 at each of the time points examined, 
namely 3 months, 1 year, and 5 years (Table 1). When 
post-discharge death rates in persons with an incident (first) 
documented episode of acute HF were examined, patients 
discharged from all greater Worcester hospitals in 2000 
also experienced slightly lower post-discharge death rates 
at 3 months, 1 year, and at 5 years compared with patients 
discharged in 1995 (Table 1).
A series of multiple regression analyses were carried 
out for purposes of determining whether the long-term 
prognosis after HF has changed during the years under 
study after controlling for a number of factors of prognostic 
importance. After controlling for age, sex, medical history of 
several comorbid conditions, acute symptoms, and laboratory 
 findings in these regression analyses, patients discharged 
from all greater Worcester hospitals in 2000, as compared 
with those discharged in 1995, were at considerably lower 
risk of dying at 3 months (OR = 0.85, 95% CI 0.73–1.00) 
and at 1 year (OR = 0.81, 95% CI = 0.71–0.92).
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Factors associated with 3 month  
and 1 year death rates
Given the high death rates experienced by hospital survivors 
of acute HF during the first year after being discharged from 
the hospital after acute decompensated HF, the demographic 
and clinical characteristics of post-discharge decedents 
were compared with survivors at 3 months and at 1 year 
(Table 2).
Overall, patients who died during the first 3 months after 
hospital discharge were generally older, had a lower BMI, 
and were more likely to have been previously diagnosed 
with anemia, chronic kidney disease, stroke, and HF than 
survivors of this high-risk period (Table 2). Patients who 
died during the first 3 months following hospital discharge 
were more likely to present with weakness at the time of their 
index hospitalization than post-discharge survivors. Patients 
dying during the first 3 months after hospital discharge 
had markedly lower blood pressure findings than patients 
who survived this period. Post-discharge decedents were 
less likely to have been prescribed angiotensin converting 
enzyme (ACE) inhibitors/angiotensin receptor blockers, 
aspirin, beta blockers, and digoxin than patients who sur-
vived the initial 3 months or 1 year after hospital discharge. 
Relatively similar characteristics were associated with an 
adverse prognosis during the first 3 months and 1 year after 
hospital discharge for HF when the characteristics of post-
discharge decedents were examined, comparing survivors 
hospitalized in 1995 with those hospitalized in 2000 (data 
not shown).
Similarly, when the characteristics of individuals 
 hospitalized with acute HF who died during the first year 
after hospital discharge were compared with those who 
did not die over this period, post-discharge decedents were 
older, had a lower BMI, and were more likely to have had 
anemia, chronic obstructive pulmonary disease (COPD), 
or HF  previously diagnosed (Table 2). Persons who died 
during the first year after hospital discharge had a dif-
ferent symptom profile at the time of hospital admission 
than persons who survived this period. Decedents in the 
first year after hospital discharge were also less likely 
than survivors to have been treated with effective cardiac 
therapies. A relatively similar profile of demographic, 
clinical, and treatment characteristics was observed in 
1-year post-discharge decedents as compared with post-
discharge survivors during each of the 2 years under study 
(data not shown).
A series of multivariable adjusted regression analyses 
were carried out for purposes of identifying factors indepen-
dently associated with post-discharge death rates at 3 months 
and 1 year, overall and separately, in the two patient cohorts 
(Table 3).
Advanced age, a history of COPD or stroke, generalized 
weakness at the time of hospital presentation, and lower eGFR 
and systolic blood pressure findings were associated with 
an increased odds of dying during the first 3 months after 
hospital discharge for decompensated HF. On the other hand, 
a higher BMI and a history of hypertension were associated 
with a lower odds of dying within 3 months after hospital 
discharge. Relatively similar prognostic factors were asso-
ciated with an adverse prognosis in each of the two study 
cohorts (1995 and 2000), though their predictive importance 
varied slightly.
Similar factors to those identified as being of prognostic 
importance during the first 3 months after hospital discharge 
were associated with an increased risk for dying during the 
first year after hospital discharge (Table 3). In addition, a 
history of previously diagnosed anemia, chronic kidney 
disease, and HF were associated with a greater likelihood 
of dying at 1 year; the presence of orthopnea at the time of 
hospital admission was associated with a lower odds of dying 
at 1 year after hospital discharge for HF. Relatively similar 
factors were associated with an increased risk of dying during 
the first year after hospital discharge in patients hospitalized 
in 1995 and in those hospitalized during 2000.
Discussion
The results of this large observational study in residents of 
metropolitan Worcester hospitalized at all greater Worcester 
medical centers with acute HF demonstrate that patients 
with this clinical syndrome experience high death rates after 
hospital discharge. Despite the overall poor prognosis of 
this condition, however, there were slight improvements in 
the crude 3-month and 1-year survival rates noted between 
Table 1 Post-discharge death rates in hospital survivors of acute 
hF at selected time points
Post-discharge  
follow-up
Death rate, % (95% CI)
All patients Incident cases  
of acute HF
1995 2000 1995 2000
3 months 19.9% 
(18.1–21.8)
18.0% 
(16.5–19.6)
15.8% 
(12.8–19.4)
13.8% 
(11.3–16.8)
1 year 41.4% 
(39.2–43.8)
38.4% 
(36.5–40.3)
29.1% 
(25.2–33.4)
28.9% 
(25.5,32.7)
5 years 84.2% 
(82.5–85.9)
81.9% 
(80.4–83.4)
72.2% 
(68.1–76.2)
66.6% 
(62.9–70.3)
Abbreviations: HF, heart failure; CI, confidence interval.
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1995 and 2000. These findings were further magnified after 
controlling for a number of demographic and clinical factors 
of long-term prognostic importance. A number of demo-
graphic and clinical characteristics were able to be identifed 
that were associated with an increased risk for dying during 
the first year after hospital discharge for acute HF.
Prognosis after hF
Residents of greater Worcester with acute HF in 1995 and 
2000 experienced high death rates after hospital discharge. 
Indeed, hospitalization for acute HF has been shown to be 
one of the strongest risk factors for dying in patients with a 
history of HF.14 On the other hand, the results of the present 
Table 2 Characteristics of post-discharge survivors and decedents of acute heart failure
Characteristic 3 months after hospital discharge 1 year after hospital discharge
Survivors 
(n = 3439)
Decedents 
(n = 789)
P-value Survivors 
(n = 2551)
Decedents 
(n = 1677)
P-value
Age (mean, years)   75.1   78.7 ,0.001   75.1   78.7 ,0.001
Age (years) n (%) n (%) n (%) n (%)
  ,65 586 (17.1) 68 (8.6) 474 (18.6) 180 (10.7)
 65–74 826 (24.0) 157 (19.9) ,0.001 641 (25.2) 342 (20.4) ,0.001
 75–84 1271 (37.0) 319 (40.4) 925 (36.3) 665 (39.7)
  $85 754 (21.9) 245 (31.1) 509 (20.0) 490 (29.2)
Male (%) 1477 (43.0) 343 (43.5) 0.82 1069 (41.9) 751 (44.8) 0.06
White race (%) 3207 (93.3) 764 (96.8) ,0.001 2356 (92.4) 1615 (96.3) ,0.001
Body mass index (%)
,25 1200 (41.8) 364 (58.2) 821 (38.5) 743 (54.6)
25.0–29.9 803 (28.0) 145 (23.2) ,0.001 614 (28.8) 334 (24.5) ,0.001
$30 868 (30.2) 117 (18.7) 700 (32.8) 285 (20.9)
Medical history (%)
Anemia 760 (22.1) 225 (28.5) ,0.001 490 (19.2) 495 (29.5) ,0.001
Coronary heart disease 1971 (57.3) 452 (57.3) 0.99 1432 (56.1) 991 (59.1) 0.06
COPD 1172 (34.1) 297 (37.6) 0.06 832 (32.6) 637 (38.0) ,0.005
Diabetes 1400 (40.7) 309 (39.2) 0.45 1023 (40.1) 686 (40.9) 0.60
hypertension 2303 (67.0) 478 (60.6) ,0.001 1722 (67.5) 1,059 (63.2) ,0.005
Peripheral vascular disease 635 (18.5) 138 (17.5) 0.56 445 (17.4) 328 (19.6) 0.09
Chronic kidney disease 762 (22.2) 223 (28.3) ,0.001 489 (19.2) 496 (29.6) ,0.001
stroke 470 (13.7) 146 (18.5) ,0.005 353 (13.8) 263 (15.7) 0.11
heart failure 2521 (73.3) 631 (80.0) ,0.001 1787 (70.1) 1365 (81.4) ,0.001
Presenting symptoms
Chest pain 1135 (33.0) 204 (25.9) ,0.001 913 (35.8) 426 (25.4) ,0.001
Dyspnea 3261 (94.8) 741 (93.9) 0.35 2428 (95.2) 1574 (93.9) 0.07
Edema 2319 (67.4) 542 (68.7) 0.52 1686 (66.1) 1175 (70.1) ,0.01
nausea/vomiting 520 (15.1) 102 (12.9) ,0.13 399 (15.6) 223 (13.3) ,0.05
Orthopnea 1232 (35.8) 229 (29.0) ,0.001 948 (37.2) 513 (30.6) ,0.001
Weakness 841 (24.5) 270 (34.2) ,0.001 596 (23.4) 515 (30.7) ,0.001
Weight gain 293 (8.5) 61 (7.7) 0.52 204 (8.0) 150 (8.9) 0.28
Laboratory findings (mean, mg/dL)
glucose 3396 (166.5) 777 (164.3) 0.50 2519 (167.7) 1654 (163.7) 0.50
Estimated gFr 3398 (64.7) 775 (58.1) ,0.001 2517 (66.6) 1656 (58.7) ,0.001
hematocrit 3391 (36.7) 780 (35.7) ,0.01
Physiologic findings 2516 (36.9) 1655 (35.8) ,0.001
systolic blood pressure (mean, mmhg) 3432 (148.3) 784 (133.9) ,0.001 2544 (150.1) 1672 (138.8) ,0.001
Diastolic blood pressure (mean, mmhg) 3396 (78.4) 769 (72.3) ,0.001 2517 (79.2) 1648 (74.2) ,0.001
heart rate (bpm) 3436 (90.6) 788 (90.0) 0.49 2548 (90.8) 1676 (89.8) 0.16
Medications
ACE inhibitors/ArBs 2025 (58.9) 330 (41.8) ,0.001 1527 (59.8) 828 (49.4) ,0.001
Aspirin 1788 (52.0) 343 (43.5) ,0.001 1355 (53.1) 776 (46.3) ,0.001
Beta blockers 1512 (44.0) 260 (33.0) ,0.001 1168 (45.8) 604 (36.0) ,0.001
Digoxin 1701 (49.5) 442 (56.0) ,0.001 1203 (47.2) 940 (56.1) ,0.001
Diuretics 3361 (97.7) 778 (98.6) 0.16 2488 (97.5) 1651 (98.5) 0.05
Abbreviations: ACE, angiotensin converting enzyme; ARB, angiotensin receptor blocker; COPD, chronic obstructive pulmonary disease; GFR, glomerular filtration rate.
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Table 3 Factors significantly associated with higher death rates at 3 months and 1 year after hospital discharge for acute 
heart failure
Characteristic OR (95% CI)
3 months 1 year
Total population 1995 cohort 2000 cohort Total population 1995 cohort 2000 cohort
Age (years)
65–74 1.42 
(1.03–1.95)
0.99 
(0.62–1.56)
1.92 
(1.21–3.05)
1.20 
(0.95–1.51)
1.11 
(0.78–1.56)
1.25 
(0.90–1.74)
75–84 1.86 
(1.38–2.51)
1.58 
(1.03–2.42)
2.09 
(1.35–3.24)
1.62 
(1.30–2.01)
1.46 
(1.05–2.04)
1.78 
(1.32–2.41)
$85 2.28 
(1.66–3.13)
1.94 
(1.22–3.08)
2.73 
(1.74–4.29)
2.14 
(1.69–2.72)
1.78 
(1.23–2.57)
2.55 
(1.85–3.53)
BMI
25.0–29.9 0.68 
(0.55–0.85)
0.58 
(0.41–0.82)
0.77 
(0.59–1.02)
0.71 
(0.60–0.84)
0.56 
(0.43–0.73)
0.83 
(0.66–1.03)
$30 0.58 
(0.46–0.73)
0.60 
(0.42–0.86)
0.58 
(0.42–0.79)
0.61 
(0.51–0.72)
0.60 
(0.45–0.78)
0.63 
(0.50–0.80)
Medical History
Anemia 1.12 
(0.91–1.37)
1.04 
(0.76–1.42)
1.16 
(0.88–1.52)
1.34 
(1.14–1.59)
1.32 
(1.02–1.72)
1.35 
(1.08–1.68)
COPD 1.22 
(1.03–1.46)
1.31 
(1.00–1.70)
1.16 
(0.92–1.47)
1.31 
(1.13–1.50)
1.21 
(0.97–1.51)
1.41 
(1.17–1.70)
hypertension 0.78 
(0.65–0.93)
0.86 
(0.66–1.13)
0.77 
(0.61–0.98)
0.82 
(0.71–0.95)
0.82 
(0.66–1.03)
0.84 
(0.69–1.02)
stroke 1.44 
(1.16–1.80)
1.53 
(1.10–2.15)
1.37 
(1.03–1.85)
1.11 
(0.92–1.34)
1.15 
(0.86–1.54)
1.08 
(0.84–1.38)
Kidney disease 1.13 
(0.89–1.43)
0.88 
(0.60–1.29)
1.32 
(0.97–1.79)
1.33 
(1.09–1.62)
1.45 
(1.05–2.01)
1.23 
(0.95–1.59)
heart failure 1.18 
(0.95–1.46)
1.29 
(0.94–1.78)
1.10 
(0.82–1.46)
1.50 
(1.27–1.78)
1.80 
(1.38–2.31)
1.30 
(1.04–1.63)
Symptoms
Chest pain 0.83 
(0.69–1.01)
0.83 
(0.63–1.10)
0.79 
(0.61–1.03)
0.68 
(0.59–0.79)
0.68 
(0.55–0.86)
0.67 
(0.55–0.82)
generalized Weakness 1.33 
(1.11–1.59)
1.41 
(1.07–1.87)
1.32 
(1.05–1.68)
1.23 
(1.06–1.43)
1.16 
(0.91–1.48)
1.31 
(1.07–1.59)
Orthopnea 0.88 
(0.74–1.05)
0.79 
(0.60–1.06)
0.98 
(0.77–1.24)
1.50 
(1.27–1.78)
1.80 
(1.38–2.31)
1.30 
(1.04–1.63)
Laboratory factors  
eGFR (mL/min/1.73 m2)
,30 1.66 
(1.25–2.22)
1.78 
(1.11–2.83)
1.60 
(1.10–2.33)
1.66 
(1.31–2.12)
1.34 
(0.90–2.00)
1.97 
(1.44–2.69)
30–44 1.47 
(1.14–1.87)
1.76 
(1.21–2.58)
1.29 
(0.93–1.80)
1.43 
(1.17–1.76)
1.02 
(0.74–1.42)
1.81 
(1.38–2.36)
45–59 1.14 
(0.89–1.44)
1.20 
(0.84–1.71)
1.06 
(0.77–1.48)
1.17 
(0.97–1.42)
1.08 
(0.81–1.45)
1.22 
(0.94–1.59)
Systolic BP (mmHg)
,100 1.50 
(1.03–2.19)
1.55 
(0.83–2.90)
1.38 
(0.86–2.24)
1.03 
(0.72–1.47)
0.94 
(0.52–1.70)
1.09 
(0.70–1.72)
100–119 1.03 
(0.71–1.49)
1.11 
(0.62–2.00)
0.95 
(0.59–1.54)
1.21 
(0.86–1.69)
1.07 
(0.62–1.85)
1.33 
(0.86–2.05)
120–139 0.84 
(0.64–1.17)
0.63 
(0.39–1.00)
0.99 
(0.69–1.41)
0.82 
(0.64–1.05)
0.60 
(0.39–0.91)
1.01 
(0.74–1.39)
140–159 0.58 
(0.43–0.78)
0.59 
(0.36–0.96)
0.55 
(0.38–0.82)
0.62 
(0.48–0.81)
0.52 
(0.34–0.80)
0.68 
(0.49–0.94)
$160 0.43 
(0.31–0.60)
0.48 
(0.29–0.81)
0.35 
(0.23–0.55)
0.50 
(0.38–0.66)
0.45 
(0.29–0.70)
0.52 
(0.36–0.73)
Abbreviations: BP, blood pressure; BMI, body mass index; CI, confidence interval; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration 
rate; Or, odds ratio.
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study showed encouraging improvements in the likelihood of 
surviving at both 3 months and 1 year in patients discharged 
from all metropolitan Worcester hospitals after acute HF in 
2000 as compared with 1995.
Although the observational nature of the investigation 
does not allow for proof of causality, the observed improve-
ments in long-term prognosis may be due to the improved 
hospital treatment of acute HF, increased use and effective-
ness of outpatient clinics for patients with HF, greater use 
of effective medical and nonpharmacologic regimens for 
hospital survivors of HF and greater adherence to these 
treatment modalities, and/or increased provider attention to 
the use of guidelines for the more effective management of 
patients with HF.
Few studies have described the long-term prognosis asso-
ciated with acute HF from a more generalizable community-
based perspective or determined whether or not the long-term 
prognosis of patients with HF has changed over time. In a 
large population-based study of Olmsted County, Minnesota, 
residents, the 5-year age-adjusted survival rates associated 
with HF improved significantly between 1991 and 1996.15 
In an investigation of more than 1000 Framingham Heart 
Study enrollees who had developed new-onset HF between 
1950 and 1999, improvements in survival after new-onset 
HF were estimated to be approximately 12% per decade for 
men and women enrolled in this seminal longitudinal study.16 
Improving trends in the 3-year survival rates after new-onset 
HF have also been demonstrated in a national study of older 
and younger patients from Scotland with HF over the period 
1986–1995.17 In a prior analysis of data collected in the 
Worcester Heart Failure Study, the authors of the present 
study described the long-term death rates associated with 
acute HF in residents of the Worcester metropolitan area 
discharged after acute HF in 2000.8 The present study extends 
the findings of these community-based studies to a relatively 
contemporary and high-risk cohort of predominantly elderly 
patients hospitalized for acute HF.
The data suggest that HF remains a highly serious and 
lethal condition for most hospitalized patients but that patients’ 
long-term prognosis has been improving. The authors hypoth-
esize that increases in the percentage of patients receiving 
cardiac medications shown to be of benefit in improving the 
long-term prognosis of patients with HF over the years under 
study may have contributed to the improvements in long-term 
prognosis noted between 1995 and 2000, though this hypoth-
esis was unable to be directly tested due to the nonrandomized 
observational nature of the present investigation.
Factors associated with an increased risk 
of dying after hospital discharge for hF
To better understand the factors affecting prognosis after 
HF, particularly for patients encountered in the broader 
community setting, the independent prognostic significance 
of several demographic and clinical factors on long-term 
survival at different time points was evaluated. At 3 months 
after hospital discharge, older age, a lower blood pressure 
and BMI, and the presence of previously diagnosed COPD, 
chronic kidney disease, stroke, and prior HF were associated 
with an increased risk of dying.
Similar prognostic variables have been identified in other 
studies evaluating short-term mortality among patients with 
HF.18,19 The association between COPD and HF is well known, 
as between 10% and 50% of all HF patients also have coexist-
ing COPD.20 In a similar fashion to HF, COPD is character-
ized by both recurrent acute exacerbations as well as by a 
general progression of disease over time.21 In addition, the 
stress on the cardiovascular system from complications of 
COPD, including hypoxia, cor pulmonale, and polycythemia, 
could theoretically exacerbate HF over time, and the pres-
ence of COPD may make it more difficult to diagnose HF.20 
Furthermore, beta blockers may not be tolerated by patients 
with both COPD and HF, and beta agonist treatment of 
COPD has been associated with increased mortality in these 
individuals.22
Previous studies have found that approximately one-
third of patients with HF will also have concomitant renal 
dysfunction,23 and as with COPD, the relationship between 
chronic and acute renal disease and adverse prognosis has 
been well documented.24 Renal dysfunction complicates 
acute and chronic treatment decisions in volume-overloaded 
patients, and renal function may be worsened by concomitant 
diuretic administration.25
The data of this present study suggest that early mortal-
ity after hospitalization for HF is strongly associated with 
advanced age, a previous history of HF, and the presence of 
other serious comorbid conditions, several of which appear 
to be secondary to chronic HF such as cardiorenal syndrome. 
Relatively similar factors were associated with an increased 
risk of dying during the first year after discharge. As has 
been noted in prior studies involving patients with acute 
HF, BMI was inversely related to mortality in the present 
study’s hospitalized cohort.26,27 It has been hypothesized that 
cardiac cachexia may contribute to the “obesity paradox” in 
HF, although the causes of cachexia among patients with 
severe HF are complex and incompletely understood.28 
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It also remains unclear whether patients who are obese are 
more likely to develop or be diagnosed with acute HF earlier 
and the extent to which obesity affects prognosis once HF 
is manifest.
Factors associated with a poor prognosis after hospital 
discharge for acute HF, including those associated with pre-
served versus systolic HF, merit further study, particularly 
with regards to better understanding the possible mechanisms 
involved so that appropriate advice and treatment regimens 
may be prescribed for patients with acute HF and its major 
subtypes.
Although considerable advances have been made and 
will continue to be made in the management of patients 
with acute HF, it is important that clinicians have a realistic 
understanding of the long-term prognosis associated with 
this clinical syndrome, including the extremely high death 
rates observed in the present study. Clinicians also need to 
be aware of factors that adversely affect patients’ long-term 
survival, which may facilitate targeted treatment toward 
specific high-risk groups or help inform decisions about 
making realistic expectations about prognosis. Decisions 
about the use of more aggressive interventions for patients 
with HF must also take into account the presence and 
effect of various comorbidities on the patient’s long-term 
survival outlook.
In the present study, post-discharge decedents were less 
likely to be discharged on effective cardiac medications, 
perhaps due to the fact that these patients were elderly, more 
likely to be hypotensive, and had worse renal function at the 
time of hospitalization compared with those who survived. 
In light of the fact that elderly patients tend to have more 
comorbid conditions, many of which also preclude the use 
of medications known to improve long-term survival, and 
since they may be less likely to be prescribed these medica-
tions due to their advanced age, it is not surprising that their 
prognosis is worse.
A recent meta-analysis examining the efficacy of ACE 
inhibitors in patients with chronic HF with preserved ejec-
tion fraction found that ACE inhibitors reduced HF-related 
hospitalizations in elderly patients.29 Another meta-analysis 
of more than 12,000 patients with systolic HF found that 
β-blockers improved mortality in elderly patients, with a 
similar relative risk reduction in mortality between elderly 
and nonelderly patients.30 The aldosterone antagonists are 
another important class of medications shown to have benefit 
in patients with systolic HF.31 Despite the known benefits 
associated with the use of these medications, they remain 
underprescribed in patients discharged from the hospital after 
decompensated HF, particularly in elderly patients.32  Treating 
these high-risk patients with evidence-based  therapies to 
optimize their long-term survival, while balancing risk, 
remains a clinical challenge and an area in need of further 
investigation.
Study strengths and limitations
The primary strength of this study is the inclusion of a large 
sample of patients hospitalized with independently validated 
HF from a well characterized New England metropolitan 
area. In addition, information was collected about a number 
of different factors that could affect the long-term prognosis 
after HF, and the rates of patient follow-up were excellent. 
The limitations of the study include the inability to system-
atically examine the long-term prognosis of patients with 
acute HF according to type of left ventricular dysfunction 
(systolic versus diastolic) given the extent of missing data 
with regard to ejection fraction findings. Also, information 
on cause-specific mortality from death certificates was 
not collected. In addition, it was not possible to assess the 
prognostic value of brain natriuretic peptide and troponin 
laboratory values as these factors were not routinely mea-
sured at the greater Worcester medical centers studied in 
1995 and 2000.
Conclusion
The results of the present study suggest that the long-term 
survival outlook for patients discharged from the hospital 
after acute HF remains poor but is improving. A number 
of characteristics associated with a poor long-term progno-
sis were identified, several of which might be effectively 
intervened upon. The present results provide further 
impetus for current efforts to improve the management of 
patients with acute HF and for the further development and 
increased use of long-term strategies to enhance patients’ 
adherence to effective medical and nonpharmacologic 
treatment regimens.
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